Review reports improved transparency in antidepressant drug trials

New research suggests manufacturers of newly developed antidepressant drugs have become more forthcoming about clinical trials that don't pan out. While the new findings are encouraging, they still hint at a fundamental shortcoming in medicine: A reliance of studies selectively reported in scientific literature, as opposed to the unvarnished results of clinical trials reported to the Food and Drug Administration.